Table 1 Summary of datasets discussed
Dataset ID | Patient count | Tumor | Drug applied | Sample acquisition | Outcome | PMID |
|---|---|---|---|---|---|---|
GSE67501 | 11 | Renal cell carcinoma | Nivolumab | Pre-treatment | Response form by RECIST and response | 27491898 |
GSE78220 | 27 | Melanoma | Pembrolizumab | Pre-treatment | OS time and response form by RECIST | 26997480 |
GSE79691 | 1 | Melanoma | Nivolumab | Post-treatment | PFS | 28193624 |
GSE91061 | 65 | Melanoma | Nivolumab | Pre-treatment or post-treatment | OS, response form by RECIST, and response | 29033130 |
58 | ||||||
56 | ||||||
GSE93157 | 65 | Head and neck squamous cell carcinoma | Nivolumab | Pre-treatment | PFS and response form by RECIST | 28487385 |
Non-squamous non-small cell lung cancer | Nivolumab or pembrolizumab | Pre-treatment | PFS and response form by RECIST | |||
Skin cutaneous melanoma | Nivolumab or pembrolizumab | Pre-treatment | PFS and response form by RECIST | |||
Squamous non-small cell lung cancer | Nivolumab or pembrolizumab | Pre-treatment | PFS and response form by RECIST | |||
GSE94873 | 360 | Melanoma | Tremelimumab | Pre-treatment or post-treatment | OS and response | 28807052 |
GSE111636 | 11 | Bladder cancer | Pembrolizumab | Not specified | Response | - |
GSE115821 | 8 | Melanoma | Unknown | Pre-treatment or post-treatment | Response | 30127394 |
GSE121810 | 29 | Glioblastoma | Pembrolizumab | Pre-treatment or post-treatment | PFI, OS, response form by RECIST, and response | 30742122 |
GSE122220 | 10 | Melanoma | Anti-PD-1 and ipilimumab | Pre-treatment or post-treatment | Response form by RECIST | – |
GSE123728 | 13 | Melanoma | Pembrolizumab | Pre-treatment or post-treatment | Recurrence | 30804515 |
GSE139050 | 6 | HER2- breast cancer | Durvalumab | Pre-treatment | Response | 33176887 |
GSE136961 | 21 | Non-small-cell lung cancer | Unknown | Pre-treatment | PFS and OS | 31959763 |
GSE140901 | 24 | Hepatocellular carcinoma | Nivolumab and/or ipilimumab, or sabatolimab (MBG453) with spartalizumab (PDR001) | Pre-treatment | PFI, OS, response form by RECIST, and response | 34414122 |
GSE165252 | 40 | Esophageal adenocarcinoma | Atezolizumab | Pre-treatment or post-treatment | PFI, OS, and response | 33504550 |
GSE165278 | 21 | Melanoma | Ipilimumab | Pre-treatment or post-treatment | OS, response duration | 33588426 |
GSE165745 | 24 | Melanoma | Pembrolizumab or nivolumab | Pre-treatment | Response | 33951424 |
GSE176307 | 89 | Urothelial cancer | Pembrolizumab/nivolumab or avelumab/atezolizumab/durvalumab | Pre-treatment | PFS and response form by RECIST | 34294892 |
GSE181815 | 10 | Thymic carcinoma | Pembrolizumab | Pre-treatment | Response form by RECIST | 34622229 |
GSE183924 | 37 | Esophageal and gastroesophageal junction adenocarcinoma | Durvalumab | Pre-treatment | RFS | 34604072 |
Chen, 2016 | 31 | Melanoma | Pembrolizumab and/or ipilimumab | Pre-treatment and/or post-treatment | Response form by RECIST, and response | 27301722 |
Cristescu, 2018 | 236 | Bladder cancer | Pembrolizumab | Pre-treatment | Response | 30309915 |
Triple-negative breast cancer | Pembrolizumab | Pre-treatment | Response | |||
ER + HER2-breast cancer | Pembrolizumab | Pre-treatment | Response | |||
Colorectal adenocarcinoma | Pembrolizumab | Pre-treatment | Response | |||
Head and neck squamous cell carcinoma | Pembrolizumab | Pre-treatment | Response | |||
Melanoma | Pembrolizumab | Pre-treatment | Response | |||
Small cell lung cancer | Pembrolizumab | Pre-treatment | Response | |||
Gide, 2019 | 74 | Melanoma | Pembrolizumab and/or nivolumab and/or ipilimumab | Pre-treatment | PFI, OS, response form by RECIST, and response | 30753825 |
Liu, 2019 | 121 | Melanoma | Nivolumab or pembrolizumab | Pre-treatment | PFS, OS, response form by RECIST, and response | 31792460 |
Mariathasan, 2018 | 348 | Urothelial cancer | Atezolizumab | Pre-treatment | OS, response form by RECIST, and response | 29443960 |
VanAllen, 2015 | 42 | Melanoma | Ipilimumab | Pre-treatment | PFS, OS, response form by RECIST, and response | 26359337 |